Statement: There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.
Primary_evidence: Adverse Events 1:   Total: 5/95 (5.26%)   Febrile neutropenia 0/95 (0.00%)   Neutropenia 0/95 (0.00%)   Atrial fibrillation 0/95 (0.00%)   Pleuropericarditis 0/95 (0.00%)   Vomiting 0/95 (0.00%)   Pryexia 0/95 (0.00%)   Anaphylactic shock 1/95 (1.05%)   Gastroenteritis 0/95 (0.00%)   Fibula fracture 1/95 (1.05%)   Tibia fracture 1/95 (1.05%)   Intervertebral disc protrusion 0/95 (0.00%) Adverse Events 2:   Total: 3/20 (15.00%)   Febrile neutropenia 0/20 (0.00%)   Neutropenia 0/20 (0.00%)   Atrial fibrillation 1/20 (5.00%)   Pleuropericarditis 1/20 (5.00%)   Vomiting 0/20 (0.00%)   Pryexia 0/20 (0.00%)   Anaphylactic shock 0/20 (0.00%)   Gastroenteritis 1/20 (5.00%)   Fibula fracture 0/20 (0.00%)   Tibia fracture 0/20 (0.00%)   Intervertebral disc protrusion 1/20 (5.00%)